-
The ACCORD trial has been newsworthy in the last several months primarily due to the early results of increased cardiovascular events associated with very tight glucose control.
-
Everolimus is the newest oral kinase inhibitor approved for the treatment of advanced renal cell carcinoma.
-
Almost one-fifth of Medicare patients who were discharged from a hospital were rehospitalized within 30 days, and about a third were rehospitalized within 90 days. Most of these readmissions were not planned.
-
We don't have the slightest idea whether evidence of gallbladder dyskinesia should warrant cholecystectomy or not.
-
Once-a-week rosuvastatin therapy was well tolerated in patients with a history of adverse events to one or more statins and led to significantly improved lipoprotein changes.
-
-
The FDA is requiring the manufacturers of metoclopramide (Reglan®) include a boxed warning on their labeling regarding the risk of long-term or high-dose use and tardive dyskinesia.
-
Modafinil (Provigil®) is a wake-promoting medication used to treat narcolepsy and other sleep disorders.
-
What is the best dose of aspirin for patients taking dual therapy with clopidogrel to prevent cardiovascular events?
-
Increasing evidence suggests that proton pump inhibitors (PPIs) may attenuate the effect of clopidogrel on platelet aggregation.